RxDoctor Payments Data

Brittany Hefetz

Family · Ridgewood, NJNPI 1871143917

Payments from drug & device makers

$660in general payments, 2019–2025

Across 38 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$150
  • AstraZeneca$146
  • Boston Scientific$89
  • Sanofi$44
  • Jazz Pharmaceuticals Inc.$43
  • Advanced Respiratory, Inc$30
  • plus $159 from 9 others

What the payments were for

  • Food & beverage$660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$660 in reported general payments places this provider in the 65th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$85,226
Medicare patients
420
Services billed
1,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$61,706
Spiriva RespimatTiotropium Bromide23$15,607
Breo ElliptaFluticasone/Vilanterol23$12,494
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,734
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$6,195
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$5,242
SymbicortBudesonide/Formoterol Fumarate13$3,494
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,447
Albuterol Sulfate HfaAlbuterol Sulfate45$1,718
Wixela InhubFluticasone Propion/Salmeterol11$1,354
Azelastine-FluticasoneAzelastine/Fluticasone12$1,315
Ventolin HfaAlbuterol Sulfate13$833
Doxepin Hcl11$494
Fluticasone Propionate25$401
Gabapentin20$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$150$81,93496 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$27$21,80234 claims
AstraZenecaSymbicort$146$3,49413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,692 family providers in New Jersey.

Other family in Ridgewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →